
    
      A Phase Ia/Ib, Open-Label, Multicentre, Two-Part Study to Assess the Safety, Tolerability,
      Pharmacokinetics and Efficacy of AZD1208 Administered Daily in Adult Patients with Recurrent
      or Refractory Acute Myelogenous Leukemia (AML).
    
  